Market News AIOpen the app

PRLD stock news · Prelude Therapeutics

Stories about Prelude Therapeutics (PRLD) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for PRLD

Follow Prelude Therapeutics (PRLD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PRLD
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 9:09 AM ET · Market

    Prelude Therapeutics shared its third quarter 2026 results, showing a solid cash position and progress in its studies.

    Good for PRLD

    Prelude reported $142.7 million in cash, expected to fund operations into the second quarter of 2028, and a Lilly study agreement. This is a positive update for Prelude.

  2. Sep 10, 2026, 7:50 AM ET · Trial

    Prelude Therapeutics says the FDA has approved its first study for a new breast cancer drug.

    Good for PRLD

    The FDA cleared Prelude's IND to start a Phase 1 study of PRT13722; this is positive for Prelude.